Celgene chief aims to double sales to $12B by 2017

Celgene CEO Bob Hugin--courtesy of Celgene.

Celgene ($CELG) captured the center ring at the J.P. Morgan conference on its opening day Monday. Company CEO Bob Hugin boldly mapped out a 5-year plan to double sales and highlighted upbeat Phase III data on its psoriasis drug apremilast that he believes will set the stage for regulatory approval on both sides of the Atlantic. Report